Publications by authors named "Michela Sibilla"
Somatostatin and its analogs have been for years a mainstay treatment for a variety of hypersecretory conditions and neoplasms of the endocrine system. This chapter summarizes their pharmacological properties, their indication in the context of acromegaly, and the best way to handle this class of drugs for the treatment of the patient with acromegaly.
View Article and Find Full Text PDFArticle Synopsis
- * While there are improvements in body composition, bone health, and quality of life, there isn’t enough evidence to prove it significantly reduces cardiovascular events or mortality, and treatment can be quite expensive.
- * It's advised to start GH therapy at low doses for optimal results and close monitoring due to potential risks like glucose intolerance and recurrence of tumors or cancer over time.
Purpose: The desmopressin daily dose requirement is highly variable among patients with arginine vasopressin (AVP) deficiency (i.e. central diabetes insipidus) and few studies to date have evaluated this topic, with often inconclusive results.
View Article and Find Full Text PDFContext: Hyponatremia is associated with increased risk of osteoporosis and fractures. The impact of hyponatremia on non-invasive indices of bone quality, however, is unknown.
Objective: To evaluate whether trabecular bone microarchitecture, assessed non-invasively by trabecular bone score (TBS), is altered in patients with hyponatremia.
Purpose: Prolactin (PRL)-secreting tumours are associated with infertility and can be reverted by dopamine agonist (DA) therapy. The suspension of DA is recommended once pregnancy is established, as all DAs cross the placenta. The aim of the study was to evaluate the rate of maternal-foetal complications in women treated with cabergoline (CAB) or bromocriptine (BRM) for prolactinoma during gestation and the effect of pregnancy on prolactinoma progression.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the relationship between prolactin (PRL) levels and pituitary abnormalities in a diverse group of patients with hyperprolactinemia, as existing guidelines primarily focus on women.
- Researchers analyzed data from 1,253 patients, identifying 139 who met criteria for inclusion; findings revealed that 76.3% had pituitary disease, with PRL levels showing limited effectiveness in predicting abnormalities, particularly when high PRL values were excluded.
- The conclusion highlights a significant occurrence of pituitary issues in hyperPRL patients, suggesting that MRI scans are essential for diagnosis, emphasizing the need for further research to clarify PRL thresholds for imaging.